ANZUPGO

This brand name is authorized in Austria, Cyprus, Estonia, France, Italy, Lithuania.

Active ingredients

The drug ANZUPGO contains one active pharmaceutical ingredient (API):

1	Delgocitinib UNII 9L0Q8KK220 - DELGOCITINIB
	Delgocitinib is a pan Janus kinase (JAK) inhibitor that targets the activity of all four members of the JAK family of enzymes consisting of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) in a concentration dependent manner.
	Read more about Delgocitinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ANZUPGO Cream	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D11AH11		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3090248, 3090259
FR	Base de données publique des médicaments	61015604
IT	Agenzia del Farmaco	051622013, 051622025
LT	Valstybinė vaistų kontrolės tarnyba	1101302, 1101303